3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Leukemia, Myeloid, Accelerated Phase
4
Leukemia
4
Blast Crisis
4
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Neoplasms by Histologic Type
1
Neoplasms
1
Myeloproliferative Disorders
1
Lymphoma
1
Leukemia, Myeloid
1
Hematologic Diseases
1
Burkitt Lymphoma
1
Bone Marrow Diseases
1
Interventions
ruxolitinib
9
fludarabine phosphate
8
fludarabine
8
Whole-Body Irradiation
8
Specimen Handling
7
Cytarabine
7
Cyclophosphamide
7
Mycophenolic Acid
6
Tacrolimus
5
Injections
5
Busulfan
5
Biopsy
5
Azacitidine
5
Stem Cell Transplantation
4
Sirolimus
4
Peripheral Blood Stem Cell Transplantation
4
Melphalan
4
Granulocyte Colony-Stimulating Factor
4
CPX-351
4
venetoclax
3
luspatercept
3
decitabine and cedazuridine drug combination
3
Liposomes
3
Idarubicin
3
Daunorubicin
3
Cyclosporine
3
Blood Specimen Collection
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
selinexor
2
nilotinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
ponatinib
×
90 days
×
Clear all
NCT02467270
2026-03-17
OPTIC
Takeda
Phase 2
Completed
283 enrolled
31 charts